Mitsubishi Tanabe Pharma Corp (4508):企業の財務・戦略的SWOT分析

◆英語タイトル:Mitsubishi Tanabe Pharma Corp (4508) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C4820
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:57
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Mitsubishi Tanabe Pharma Corp (4508) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Mitsubishi Tanabe Pharma Corp (Mitsubishi Tanabe), a subsidiary of Mitsubishi Chemical Holdings Corp, identifies, develops, manufactures, procures and commercializes ethical drugs and over-the-counter (OTC) pharmaceutical products. The company develops ethical drugs for autoimmune disease, diabetes, kidney diseases, central nervous system (CNS) disorders and others. It also develops vaccines for preventing various infectious diseases. Mitsubishi Tanabe’s major brands include remicade, simponi, tenelia, ceredist, lexapro, flucort f, nanpao, alegysal bien and okinazole. The company markets its products to wholesalers, hospitals, clinics, and drugstores. It has subsidiaries in Asia, Europe and North America. Mitsubishi Tanabe is headquartered in Chuo-ku, Osaka, Japan.

Mitsubishi Tanabe Pharma Corp Key Recent Developments

Jul 02,2018: Mitsubishi Tanabe Pharma and Osaka University co-found the Department of Neuro-Medical Science – Toward the Innovative Drug Discovery for refractory Neurological Diseases
Jul 02,2018: Mitsubishi Tanabe Pharma and Osaka University co-found the “Department of Neuro-Medical Science”
Jul 02,2018: Mitsubishi Tanabe Pharma: Open Call for Applicants for investigator-Initiated Clinical Research Funds
May 30,2018: Daiichi Sankyo Announces Launch of Immune-mediated Inflammatory Diseases Consortium for Drug Development
May 30,2018: Notice Regarding Establishment of Immune-mediated Inflammatory Diseases Consortium for Drug Development

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Mitsubishi Tanabe Pharma Corp – Key Facts 6
Mitsubishi Tanabe Pharma Corp – Key Employees 7
Mitsubishi Tanabe Pharma Corp – Key Employee Biographies 8
Mitsubishi Tanabe Pharma Corp – Major Products and Services 9
Mitsubishi Tanabe Pharma Corp – History 11
Mitsubishi Tanabe Pharma Corp – Company Statement 18
Mitsubishi Tanabe Pharma Corp – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Joint Venture 22
Section 2 – Company Analysis 23
Company Overview 23
Mitsubishi Tanabe Pharma Corp – Business Description 24
Product Category: Ethical Drugs 24
Performance 24
Product Category: OTC Products 24
Performance 24
Product Category: Others 24
Performance 24
Product Category: Royalty Revenue 25
Performance 25
Geographical Segment: Asia 25
Performance 25
Geographical Segment: Europe 25
Performance 25
Geographical Segment: Japan 25
Performance 25
Geographical Segment: North America 25
Performance 25
Geographical Segment: Others 25
Performance 25
R&D Overview 25
Mitsubishi Tanabe Pharma Corp – Corporate Strategy 26
Mitsubishi Tanabe Pharma Corp – SWOT Analysis 27
SWOT Analysis – Overview 27
Mitsubishi Tanabe Pharma Corp – Strengths 27
Mitsubishi Tanabe Pharma Corp – Weaknesses 28
Mitsubishi Tanabe Pharma Corp – Opportunities 29
Mitsubishi Tanabe Pharma Corp – Threats 30
Mitsubishi Tanabe Pharma Corp – Key Competitors 31
Section 3 – Company Financial Ratios 32
Financial Ratios – Capital Market Ratios 32
Financial Ratios – Annual Ratios 33
Performance Chart 36
Financial Performance 36
Financial Ratios – Interim Ratios 37
Financial Ratios – Ratio Charts 38
Section 4 – Company’s Lifesciences Financial Deals and Alliances 39
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 39
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 40
Mitsubishi Tanabe Pharma Corp, Recent Deals Summary 41
Section 5 – Company’s Recent Developments 42
Jul 02, 2018: Mitsubishi Tanabe Pharma and Osaka University co-found the Department of Neuro-Medical Science – Toward the Innovative Drug Discovery for refractory Neurological Diseases 42
Jul 02, 2018: Mitsubishi Tanabe Pharma and Osaka University co-found the “Department of Neuro-Medical Science” 43
Jul 02, 2018: Mitsubishi Tanabe Pharma: Open Call for Applicants for investigator-Initiated Clinical Research Funds 44
May 30, 2018: Daiichi Sankyo Announces Launch of Immune-mediated Inflammatory Diseases Consortium for Drug Development 45
May 30, 2018: Notice Regarding Establishment of Immune-mediated Inflammatory Diseases Consortium for Drug Development 46
Mar 26, 2018: Mitsubishi Tanabe Pharma and Hitachi Utilize AI Technology to Begin Collaborative Creation for Improving Efficiency of Clinical Trials for New Drug Development 47
Dec 13, 2017: Strategic Collaboration for the Development of the Antibody Drug to Treat Neurodegenerative Diseases including ALS 48
Nov 01, 2017: Mitsubishi Tanabe Pharma: Financial Results for the First Six Months of the Fiscal year ending March 31, 2018 49
Oct 11, 2017: Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Conduct “JOINUS,” a New Drug Discovery Program Using Drug-Repositioning Compound Library 51
Sep 29, 2017: MT Pharma: Organizational Change and Personnel Change 52
Section 6 – Appendix 53
Methodology 53
Ratio Definitions 53
About GlobalData 57
Contact Us 57
Disclaimer 57

List of Tables
Mitsubishi Tanabe Pharma Corp, Key Facts 6
Mitsubishi Tanabe Pharma Corp, Key Employees 7
Mitsubishi Tanabe Pharma Corp, Key Employee Biographies 8
Mitsubishi Tanabe Pharma Corp, Major Products and Services 9
Mitsubishi Tanabe Pharma Corp, History 11
Mitsubishi Tanabe Pharma Corp, Other Locations 19
Mitsubishi Tanabe Pharma Corp, Subsidiaries 20
Mitsubishi Tanabe Pharma Corp, Joint Venture 22
Mitsubishi Tanabe Pharma Corp, Key Competitors 31
Mitsubishi Tanabe Pharma Corp, Ratios based on current share price 32
Mitsubishi Tanabe Pharma Corp, Annual Ratios 33
Mitsubishi Tanabe Pharma Corp, Annual Ratios (Cont...1) 34
Mitsubishi Tanabe Pharma Corp, Annual Ratios (Cont...2) 35
Mitsubishi Tanabe Pharma Corp, Interim Ratios 37
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 39
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 40
Mitsubishi Tanabe Pharma Corp, Recent Deals Summary 41
Currency Codes 53
Capital Market Ratios 53
Equity Ratios 54
Profitability Ratios 54
Cost Ratios 55
Liquidity Ratios 55
Leverage Ratios 56
Efficiency Ratios 56

List of Figures
Mitsubishi Tanabe Pharma Corp, Performance Chart (2014 - 2018) 36
Mitsubishi Tanabe Pharma Corp, Ratio Charts 38
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 39
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 40

★海外企業調査レポート[Mitsubishi Tanabe Pharma Corp (4508):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Prakash Constrowell Limited
    Prakash Constrowell Limited - Strategy, SWOT and Corporate Finance Report Summary Prakash Constrowell Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Omnicell Inc (OMCL)-医療機器分野:企業M&A・提携分析
    Summary Omnicell Inc (Omnicell) is a provider of automation and business analytics software solutions. It provides medication control and patient safety solutions to enhance operational efficiency and patient care in acute healthcare facilities. The company offers automation solutions such as medica …
  • Capstone Turbine Corp (CPST):電力:M&Aディール及び事業提携情報
    Summary Capstone Turbine Corp (CPST) is an energy company. It develops, manufactures, markets, and services microturbine technology solutions and power generation systems. The company integrates air bearing technology, advanced combustion technology, and power electronics to form efficient and ultra …
  • EWE AG:電力:M&Aディール及び事業提携情報
    Summary EWE AG (EWE) operates in energy, telecommunication and information technology businesses. The company is involved in generation and transmission of energy, gas storage and waste water treatment. EWE plans, builds and operates renewable power generation plants globally. The company operates c …
  • Starpharma Holdings Ltd (SPL):企業の財務・戦略的SWOT分析
    Starpharma Holdings Ltd (SPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Caterpillar Inc.:戦略・SWOT・企業財務分析
    Caterpillar Inc. - Strategy, SWOT and Corporate Finance Report Summary Caterpillar Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • SPAR Osterreichische Warenhandels AG:企業の戦略的SWOT分析
    SPAR Osterreichische Warenhandels AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • SGD S.A.:企業の戦略・SWOT・財務情報
    SGD S.A. - Strategy, SWOT and Corporate Finance Report Summary SGD S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Ca Immobilien Anlagen Ag
    Ca Immobilien Anlagen Ag - Strategy, SWOT and Corporate Finance Report Summary Ca Immobilien Anlagen Ag - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Asarco LLC:企業の戦略・SWOT・財務分析
    Asarco LLC - Strategy, SWOT and Corporate Finance Report Summary Asarco LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Samsung Heavy Industries Co., Ltd.
    Samsung Heavy Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Samsung Heavy Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Larsen & Toubro Ltd (LT):企業の財務・戦略的SWOT分析
    Larsen & Toubro Ltd (LT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • MIE Holdings Corp (1555):石油・ガス:M&Aディール及び事業提携情報
    Summary MIE Holdings Corp (MIEH), a subsidiary of Far East Energy Ltd is an oil and gas company that carries out exploration, development and production activities. The company operates Daan, Moliqing and Miao 3 oilfields in the Songliao Basin. Its Daan oilfield is located in Daan City that covers a …
  • AGF Management Limited:企業の戦略・SWOT・財務情報
    AGF Management Limited - Strategy, SWOT and Corporate Finance Report Summary AGF Management Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Ligand Pharmaceuticals Inc (LGND):製薬・医療:M&Aディール及び事業提携情報
    Summary Ligand Pharmaceuticals Inc (Ligand) develops and acquires technologies that help in discovery and development of medicines. The company employs research technologies including nuclear receptor assays, formulation science, high throughput computer screening, antibody discovery technologies an …
  • Lennox International Inc.:企業の戦略・SWOT・財務情報
    Lennox International Inc. - Strategy, SWOT and Corporate Finance Report Summary Lennox International Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Coal India Ltd:戦略・SWOT・企業財務分析
    Coal India Ltd - Strategy, SWOT and Corporate Finance Report Summary Coal India Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Glenmark Pharmaceuticals Ltd (GLENMARK):企業の財務・戦略的SWOT分析
    Glenmark Pharmaceuticals Ltd (GLENMARK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Suedzucker Ag:企業の戦略・SWOT・財務分析
    Suedzucker Ag - Strategy, SWOT and Corporate Finance Report Summary Suedzucker Ag - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Theraclion SA (ALTHE):企業の財務・戦略的SWOT分析
    Summary Theraclion SA (Theraclion) is a medical device company that designs, markets, and develops high-intensity focused therapeutic ultrasound devices and equipment; and offers technical support services. The company offers echotherapy solution that combines HIFU therapy with ultrasound as a syste …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆